



Amicus Therapeutics, Inc.



FOLD NASDAQ

Pharmaceuticals - Diversified

Market Capitalization USD:

\$132.87 mm

CONCERN LEVEL: LOW

- 1 The CEO's total remuneration is within the typical market range for the relevant industry and market cap.
- 2 The ratio between the CEO's pay and the median pay of the other named executive officers is 3X or less.
- 3 The CEO's annual cash incentives rose or fell in line with annual performance. 
- 4 The CEO received no more than one annual cash bonus this fiscal year.
- 5 The CEO's equity remuneration reflected the company's share price movement over the last five years.
- 6 The company only pays long-term incentives to the CEO for above median performance against a peer group.
- 7 The company's dilution from equity incentives is 10 percent or less.
- 8 Unvested equity lapses when the CEO's employment is terminated. 
- 9 The CEO's potential cash severance payment is capped at two times annual cash remuneration.
- 10 The accrued benefits of the CEO's post-retirement income are within the typical market range for the relevant market cap bracket.

CEO: John F. Crowley

Age: 45

CEO Since: 2011

	2009	2010	2011
Base Salary	\$437,750	\$446,505	\$461,356
Discretionary Bonus	\$109,438	\$242,229	\$174,400
Annual Cash Incentive	\$0	\$0	\$0
Benefits and Perquisites	\$1,191,368	\$1,017,174	\$1,822,251
TOTAL ANNUAL COMPENSATION	\$1,738,556	\$1,705,908	\$2,458,007
Increase in Post-Retirement Benefits	\$0	\$0	\$0
Stock Option Awards	\$1,202,336	\$109,106	\$497,088
Stock Awards	\$0	\$0	\$0
TOTAL COMPENSATION	\$2,940,892	\$1,815,014	\$2,955,095
Median of Other Named Executive Officers Total Compensation	\$1,142,743	\$500,869	\$1,084,220
Value Realized on Exercise of Stock Option	\$2,285	\$0	\$0
Value Realized on Vesting of Stock	\$0	\$0	\$0
TOTAL REALIZED EQUITY COMPENSATION	\$2,285	\$0	\$0

Proxy Date: 27 Apr 2012

Annual Meeting Date: 13 Jun 2012

Equity Reserves: 0.00%


Stock Option Run Rate: 3.85%

Amicus Therapeutics, Inc.

FOLD NASDAQ

Pharmaceuticals - Diversified

Market Capitalization USD: **\$132.87 mm**



Peer Comparisons (TRBC) =Pharmaceuticals - Diversified

		Total Summary CEO Compensation			Market Cap
Ticker	Company Name	2009	2010	2011	
FOLD	Amicus Therapeutics, Inc.	\$2,940,892	\$1,815,014	\$2,955,095	\$132,865,655
ACHN	Achillion Pharmaceuticals, Inc.		\$1,913,823	\$1,422,901	\$329,072,396
SVNT	Savient Pharmaceuticals, Inc.	\$1,414,685	\$639,132	\$8,790,708	\$292,731,799
CHTP	Chelsea Therapeutics International, Ltd.	\$1,169,018	\$1,245,307	\$954,405	\$237,107,292
SGMO	Sangamo BioSciences, Inc.	\$1,822,020	\$1,907,452		\$228,217,399
ARNA	Arena Pharmaceuticals, Inc.	\$1,563,992	\$1,193,451	\$1,254,585	\$210,185,372
INHX	Inhibitex, Inc.	\$492,936	\$699,094		\$192,336,211

To insure consistency, peer comparisons are based on a combination of TRBC Industry and Sector classifications and company market caps. Missing peer pay figures for 2011 are due to differences in company filing schedules.

Pay Peer Group

ACADIA Pharmaceuticals, Affymax, Alexza Pharmaceuticals, Alnylam Pharmaceuticals, ArQule, Cytokinetics, Enzo Biochem, Enzon Pharmaceuticals, PolyMedix, Rigel Pharmaceuticals, Synta Pharmaceuticals.

Performance Peer Group

NA

COMPENSATION COMMITTEE MEMBERS

Director	Membership	Age	Gender	Tenure	Independence
Margaret G. McGlynn	Chairman	52	Female	3	Outside
James N. Topper	Member	50	Male	8	Outside Related
Michael G. Raab	Member	47	Male	8	Outside
Sol J. Barer	Member	65	Male	3	Outside